Comparing Intelligent Bio Solutions (NASDAQ:INBS) and Penumbra (NYSE:PEN)

Penumbra (NYSE:PEN) and Intelligent Bio Solutions (NASDAQ:INBS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Penumbra and Intelligent Bio Solutions, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0	3	12	1	2.88
Intelligent Bio Solutions	0	0	0	0	0.00

Penumbra currently has a consensus price target of $292.64, suggesting a potential upside of 2.29%. Given Penumbra’s stronger consensus rating and higher probable upside, equities analysts plainly believe Penumbra is more favorable than Intelligent Bio Solutions.

Risk and Volatility

Penumbra has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.72, indicating that its share price is 372% more volatile than the S&P 500.

Profitability

This table compares Penumbra and Intelligent Bio Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Penumbra	1.17%	9.74%	7.35%
Intelligent Bio Solutions	-323.79%	-146.03%	-83.62%

Valuation and Earnings

This table compares Penumbra and Intelligent Bio Solutions”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.19 billion	9.22	$90.95 million	$0.34	841.49
Intelligent Bio Solutions	$3.03 million	4.65	-$10.16 million	N/A	N/A

Penumbra has higher revenue and earnings than Intelligent Bio Solutions.

Insider & Institutional Ownership

88.9% of Penumbra shares are held by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are held by institutional investors. 5.0% of Penumbra shares are held by insiders. Comparatively, 0.3% of Intelligent Bio Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Penumbra beats Intelligent Bio Solutions on 12 of the 13 factors compared between the two stocks.

About Penumbra

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.